The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase - Kantor, P F; Lucien, A; Kozak, R (Circ Res, 2000)
et al.